Suhuang cough capsule entered the 2020 edition of Pharmacopoeia of the People's Republic of China (Part 1) as one of the new Chinese medicine varieties. In the 2020 edition of Chinese Pharmacopoeia, 319 new varieties were added, 3177 were revised, 10 were no longer included, and 4 varieties were adjusted and merged, totaling 5911 varieties. A total of 2711 kinds of traditional Chinese medicine were collected, of which 117 were added and 452 were revised.

Suhuang Zhike capsule is composed of nine traditional Chinese medicines, such as ephedra and perilla-leaf, which can relieve wind and release lung, relieve cough and relieve throat. It is an exclusive product born after Professor Chao Enxiang, a Chinese medical master, combined with more than 40 years of clinical experience, creatively proposed the theory of "treating cough from wind" and "treating cough from wind", breaking through the academic bottleneck of "all diseases are difficult to cure cough". It is mainly aimed at subacute and chronic cough symptoms such as cough after cold and cough variant asthma. It is the only Chinese patent medicine recommended by Western Medicine "Cough Diagnosis and Treatment Guide" (2015), and has won the third prize of Beijing Science and Technology Award, Clinical value Chinese patent medicine brand and other honors.

It is reported that the 2020 edition of the "Chinese Pharmacopoeia" will be implemented on December 30, 2020, and will further meet the needs of the national essential drugs catalog and basic medical insurance catalog varieties, which is conducive to improving the overall level of China's drug standards, ensuring public drug safety, promoting the adjustment of pharmaceutical industry structure, and promoting China's pharmaceutical products into the international market. To realize the leap from pharmaceutical power to pharmaceutical power.